Google-backed 23andMe hits major milestone: 100,000 users in DNA database
By Peter Delevett,
Mercury News
| 06. 15. 2011
Mountain View genomics startup 23andMe just hit a milestone: As of Wednesday, 100,000 people have uploaded their genetic code to the 4-year-old company's database.
Co-founder and CEO Anne Wojcicki says her scientists now have one of the world's largest genetic databases, which will enable them to do "a tremendous amount of discovery" into the possible causes of ailments such as Parkinson's disease. The company is also helping customers better understand their own DNA, the genetic blueprint that determines everything from whether someone is prone to breast cancer to whether their urine smells funny after eating asparagus (for 70 percent of us, the answer's yes on the latter).
But critics worry that 23andMe and other such genomics companies are misleading consumers with DNA profiles that don't tell nearly as much about their health -- good or bad -- as many might think. And in 23andMe's case, they've raised questions about the fact that one of the company's chief financial backers is Google (GOOG) -- whose co-founder, Sergey Brin, is Wojcicki's husband.
In a rare interview, Wojcicki spoke frankly about those controversies...
Related Articles
By Hannah Devlin, The Guardian | 05.14.2024
Photo by Kind and Curious from Unsplash
When Great Ormond Street hospital (Gosh) published the results of its gene therapy trial for “bubble baby” syndrome it was hailed as a medical breakthrough. The treatment had a more than 95% success...
By Victoria Bisset and Adela Suliman, The Washington Post | 05.09.2024
Photo by CDC from Unsplash
A baby girl born with profound genetic deafness can now hear unaided after receiving a “groundbreaking” gene therapy trial, Britain’s National Health Service said Thursday.
Opal Sandy, an 18-month-old from Oxfordshire, England, is the first...
By Carrie Arnold, Nature Biotechnology | 04.17.2024
Tome Biosciences came out of stealth mode on 12 December with a haul of over $200 million to develop the company’s gene editing platform. Tome’s first order of business was to snap up Replace Therapeutics to expand its toolkit to...
By Charlotte Hu, Vox | 05.06.2024
Medicine has entered a new era in which scientists have the tools to change human genetics directly, creating the potential to treat or even permanently cure diseases by editing a few strands of troublesome DNA. And CRISPR, the gene-editing...